Market capitalization | $2.56b |
Enterprise Value | $1.93b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 147.71 |
P/S ratio (TTM) P/S ratio | 196.33 |
P/B ratio (TTM) P/B ratio | 3.89 |
Revenue growth (TTM) Revenue growth | 54.12% |
Revenue (TTM) Revenue | $13.05m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
13 Analysts have issued a Janux Therapeutics Inc forecast:
13 Analysts have issued a Janux Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 13 13 |
54%
54%
|
|
Gross Profit | 11 11 |
65%
65%
|
|
EBITDA | -84 -84 |
14%
14%
|
EBIT (Operating Income) EBIT | -86 -86 |
14%
14%
|
Net Profit | -61 -61 |
3%
3%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Janux Therapeutics, Inc. operates preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in La Jolla, CA.
Head office | United States |
CEO | David Campbell |
Employees | 64 |
Founded | 2017 |
Website | www.januxrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.